Holen Sie sich die Stockscreener-App
527.22
2.53%
12.99
Handel nachbörslich:
528.09
0.87
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$514.23
Offen:
$516.34
24-Stunden-Volumen:
2.57M
Relative Volume:
1.11
Marktkapitalisierung:
$195.93B
Einnahmen:
$44.56B
Nettoeinkommen (Verlust:
$6.72B
KGV:
29.72
EPS:
17.7387
Netto-Cashflow:
$6.29B
1W Leistung:
+7.71%
1M Leistung:
+13.53%
6M Leistung:
+0.26%
1J Leistung:
+17.33%
1-Tages-Spanne:
$514.00
$530.00
1-Wochen-Bereich:
$490.25
$530.00
52-Wochen-Spanne:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
527.22 | 184.37B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.61 | 134.19B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
584.05 | 44.72B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
120.39 | 32.52B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
330.98 | 31.41B | 3.17B | 642.63M | 516.49M | 10.77 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher Scientific and PRECISE Partner on Singapore Proteomics Study - Clinical Lab Products
Barclays Adjusts Price Target on Thermo Fisher Scientific to $625 From $650, Maintains Overweight Rating - marketscreener.com
A Look At Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Volatility - Yahoo Finance
Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities - BioSpace
Thermo Fisher Scientific Inc (TMO) Shares Surge 3.6% -- What GF Score of 88 Tells Investors - GuruFocus
Thermo Fisher Scientific Inc. stock rises Monday, outperforms market - MarketWatch
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand R - PharmiWeb.com
Small Molecule Innovator API CDMO Market Outlook, 2026-2033Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry - Yahoo Finance UK
TD Cowen lowers Thermo Fisher stock price target on valuation reset - Investing.com
Thermo Fisher Scientific, HealthVerity Partner to Expand Real-World Data Capabilities - Contract Pharma
Thermo Fisher Scientific Inc. and HealthVerity Collaborate To Expand Real-World Data Capabilities - marketscreener.com
TD Cowen Adjusts Price Target on Thermo Fisher Scientific to $625 From $683, Maintains Buy Rating - marketscreener.com
Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - GlobeNewswire Inc.
Goldman Sachs Adjusts PT on Thermo Fisher Scientific to $610 From $650, Maintains Buy Rating - marketscreener.com
Thermo Fisher stock may benefit following collaboration with PRECISE - MSN
Thermo Fisher PRECISE SG100K Partnership Puts Valuation And Growth In Focus - Yahoo Finance
Wallace Advisory Group Reduces Stake in Thermo Fisher Scientific - National Today
Is It Too Late To Consider Thermo Fisher Scientific (TMO) After Recent Share Price Weakness? - Yahoo Finance
Thermo Fisher Launches Automated Cell Therapy System - Technology Networks
Thermo Fisher expands global biobank leadership through collaboration with PRECISE-SG100K Singapore - BioSpectrum Asia
Is Thermo Fisher Scientific (TMO) one of the best conservative stocks to buy right now? - MSN
The Market Is Selling Everything, but These 5 Stocks Aren’t Breaking Down - Investing.com
Thermo Fisher Stock May Benefit Following Collaboration With PRECISE - Yahoo Finance
Flow Cytometry Market is experiencing boost at an infinite speed - openPR.com
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - GlobeNewswire Inc.
Thermo Fisher Shares Could See Gains After Teaming Up With PRECISE - Bitget
Thermo Fisher Scientific Expands Global Biobank Leadership - National Today
Thermo Fisher Scientific and Precision Health Research Singapore Enter Strategic Collaboration to Advance Precise-SG100K Study - marketscreener.com
Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PREC - PharmiWeb.com
Thermo Fisher, Singapore’s PRECISE Partner on Population-Scale Proteomics Biobank - Contract Pharma
Thermo Fisher Scientific Partners PRECISE To Advance Singapore’s Landmark SG100K Biobank Study - BioPharma APAC
TMO Partners with Precision Health for Major Biobank Study - GuruFocus
Thermo Fisher Scientific Signs Strategic Deal With Precision Health Research, Singapore to Support PRECISE-SG100K Study - marketscreener.com
Thermo Fisher partners with Singapore biobank study By Investing.com - Investing.com India
Seer Joins Thermo Fisher Tools In Large-Scale Proteomics Effort - Benzinga
Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics - Business Wire
Thermo Fisher Saladax TDM Deal Adds Dimension To Diagnostics Growth Story - Yahoo Finance
How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Its Cell Therapy And Biologics Platforms - Sahm
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch
Thermo Fisher Scientific Inc. (TMO) stock price, news, quote and history - Yahoo Finance Singapore
Biotechnology Reagents and Kits Market Set to Witness Rapid - openPR.com
[ARS] THERMO FISHER SCIENTIFIC INC. SEC Filing - Stock Titan
Thermo Fisher (NYSE: TMO) outlines 2025 performance, CEO retention grant and 2026 pay overhaul - Stock Titan
Thermo Fisher (TMO) Poised for Growth with Upcoming Catalysts - GuruFocus
Lobbying Update: $21,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver Quantitative
Thermo Fisher Introduces Gibco CTS Compleo Fill and Finish System - Contract Pharma
Electron Microscopes Market Is Going to Boom |• Thermo Fisher Scientific • JEOL Ltd. - openPR.com
Thermo Fisher Scientific Inc. $TMO Shares Sold by Rathbones Group PLC - MarketBeat
Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals
JB Capital LLC Decreases Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):